Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Celltrion Forms JV with Nan Fung to Develop Three Biosimilars in China

publication date: Jul 19, 2019

Celltrion of South Korean will form a JV with Nan Fung Group, a Hong Kong investment firm, to develop and commercialize three Celltrion biosimilars in China. The JV, named Vcell Healthcare, will develop Celltrion biosimilars for major biologic products: Remicade, Rituxan and Herceptin. Each of the three biosimilars have been accepted for use in the US and EU, and Celltrion has already started China trials on the Remicade and Herceptin biosimilars. Vcell also plans to build a biologics facility to manufacture the products in China. Celltrion develops biosimilars and novel biologic drugs. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital